贝伐珠单抗联合化疗治疗非小细胞肺癌的效果及对T细胞亚群、免疫功能的影响  

Effect of Bevacizumab combined with chemotherapy in the treatment of non-small cell lung cancer and its influence on T cell subsets and immune function

作　　者：潘恩媛 夏琴[2] PAN Enyuan;XIA Qin(Department of Pharmacy,Anhui No.2 Provincal People’s Hospital,Anhui Province,Hefei230041,China;Department of Pharmacy,Ruijin Hospital Affiliated to Medical College of Shanghai Jiao Tong University,Shanghai200025,China)

机构地区：[1]安徽省第二人民医院药学部,安徽合肥230041 [2]上海交通大学医学院附属瑞金医院药剂科,上海200025

出　　处：《中国医药导报》2021年第29期118-121,共4页China Medical Herald

摘　　要：目的探讨贝伐珠单抗联合化疗治疗非小细胞肺癌(NSCLC)的效果及其对T细胞亚群、免疫功能的影响。方法选取2018年1月至2020年8月安徽省第二人民医院收治的80例NSCLC患者为研究对象,采用随机数字表法将其分为观察组和对照组,每组40例。对照组给予培美曲塞+铂类化疗;观察组在化疗的基础上,联合贝伐珠单抗治疗。两组均在第1天静脉滴注,以21 d为1个周期,每个周期均在第1天进行静脉滴注,共治疗2个周期。比较两组临床疗效、治疗前后T细胞亚群CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)及免疫球蛋白IgA、IgG、IgM水平的变化,并比较两组副作用的发生情况。结果治疗后,观察组临床总有效率高于对照组,差异有统计学意义(P <0.05)。两组治疗后CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)、IgA、IgG、IgM水平均低于治疗前,且观察组高于对照组,差异有统计学意义(P <0.05)。两组副作用发生率比较,差异无统计学意义(P> 0.05)。结论贝伐珠单抗联合化疗治疗NSCLC患者效果明显,可改善患者T细胞亚群、免疫功能的表达,值得应用推广。Objective To study the effect of Bevacizumab combined with chemotherapy in the treatment of non-small cell lung cancer(NSCLC) and its influence on T cell subsets and immune function.Methods Eighty NSCLC patients admitted to Anhui No.2 Provincal People’s Hospital from January 2018 to August 2020 were selected as the research subjects,they were divided into observation group and control group by random number table method,with 40 cases in each group.The control group was given Pemetrexed combined with platinum chemotherapy,and the observation group was combined with Bevacizumab on the basis of the chemotherapy.Both groups were given intravenous infusion on the first day,with a cycle of 21 days,and each cycle was given intravenous infusion on the first day for a total of two cycles.The clinical efficacy,the changes of the T cell subsets CD3^(+),CD4^(+),CD4^(+)/CD8^(+),immunoglobulin IgA,IgG,and IgM before and after treatment were compared between the two groups,and the side reaction during the treatment were compared.Results After treatment,the total clinical effective rate of observation group was higher than control group,and the difference was statistically significant(P < 0.05).After treatment,the levels of CD3^(+),CD4^(+),CD4^(+)/CD8^(+),IgA,IgG,and IgM in two groups were lower than those before trentment,and the observation group was higher than the control group,and the differences were statistically significant(P < 0.05).There was no significant difference in the incidence of side reaction between two groups during treatment(P > 0.05).Conclusion Bevacizumab combined with chemotherapy has a significant effect on the treatment of NSCLC patients,which can improve the expression of T cell subsets and immune function,and is worthy of application and promotion.

关 键 词：非小细胞肺癌 化疗 贝伐珠单抗 T细胞亚群 免疫功能 疗效 副作用 

分 类 号：R734.2[医药卫生—肿瘤]